Used primarily in pharmaceutical research, this compound is a key intermediate in the synthesis of immunomodulatory drugs, particularly those belonging to the class of cereblon E3 ligase modulators. It plays a critical role in the development of targeted protein degradation therapies, including proteolysis-targeting chimeras (PROTACs) and molecular glues. Its structure enables selective binding to cereblon, facilitating the degradation of disease-related proteins. Due to this mechanism, it is extensively studied in oncology, especially for hematological malignancies such as multiple myeloma and myelodysplastic syndromes. It is also employed in the optimization of drug candidates to improve potency, selectivity, and pharmacokinetic properties.